Tang Capital Management’s Moderna MRNA Stock Holding History

Tang Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.5M	Sell	50,000 -50,000	-50%	-$2.59M	0.16%	36
2026 Q1	$5.08M	Sell	100,000 -592,820	-86%	-$27.7M	0.26%	36
2025 Q4	$20.4M	Buy	692,820 +387,520	+127%	+$10.5M	1.01%	25
2025 Q3	$7.89M	Hold	305,300	–	–	0.3%	74
2025 Q2	$8.42M	Hold	305,300	–	–	0.43%	62
2025 Q1	$8.66M	Buy	305,300 +5,300	+2%	+$188K	0.48%	51
2024 Q4	$12.5M	Buy	+300,000	New	+$14.3M	0.83%	34
2024 Q1	–	Sell	-76,700	Closed	-$7.63M	–	120
2023 Q4	$7.63M	Hold	76,700	–	–	0.7%	38
2023 Q3	$7.92M	Hold	76,700	–	–	1.12%	31
2023 Q2	$9.32M	Sell	76,700 -60,000	-44%	-$8M	1.37%	25
2023 Q1	$21M	Buy	136,700 +56,700	+71%	+$9.35M	3.13%	7
2022 Q4	$14.4M	Buy	+80,000	New	+$13.1M	2.09%	16

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Tang Capital Management's MRNA Position: Q2 2026 in Review

Tang Capital Management reduced its Moderna (MRNA) stake by 50% in Q2 2026, selling an estimated $2.59M and leaving 50,000 shares worth $3.5M. The position accounts for 0.16% of the portfolio, ranked #36.

Tang Capital Management first reported a position in MRNA in Q4 2022 and has held it in 12 quarters since. The position peaked at $21M in Q1 2023. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Tang Capital Management held 50,000 shares of Moderna worth $3.5M as of Q2 2026.
Tang Capital Management sold 50,000 Moderna shares in Q2 2026, an estimated $2.59M.
Moderna made up 0.16% of Tang Capital Management's portfolio in Q2 2026, its #36 holding.
Tang Capital Management first reported a position in Moderna in Q4 2022 and has held it in 12 quarters since.
Tang Capital Management's Moderna position peaked at $21M in Q1 2023.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.